Moreover, the topoisomerase II inhibitor mitoxantrone induces the release of DAMPs and triggers ICD by activating eukaryotic initiation factor 2α (eIF2α) via upregulation of protein kinase RNA-like ER kinase (PERK)/general control nonderepressible 2 (GCN2) in prostate cancer cells in vitro and induces antitumor immunity in vivo [64]. Here, EIF2AK4 is linked to prostate carcinoma.